---
title: "Melanoma tumour thickness in Norway"
subtitle: "An analysis of survival trend,<br>1983â€“2019"
author: "Raju Rimal"
date: "13 June, 2023"
institute: "Department of Biostatistics<br>University of Oslo"
code-overflow: scroll
date-format: "DD MMMM YYYY"
bibliography: References.bib
citations-hover: true
preview-links: true
knitr:
  opts_chunk: 
    collapse: true
    comment: "#>" 
execute: 
  echo: false
  warning: false
format: 
  revealjs:
    transition: none
    background-transition: none
    template-partials:
      - title-slide.html
    theme: [default, custom.scss]
    logo: Images/Logos/UiO-Logo.png
    title-slide-attributes:
      data-background-color: "#FCFCFC"
      data-background-image: Images/melo.svg
      data-background-opacity: "0.75"
      data-background-size: auto 80%
      data-background-position: 90% center
editor_options: 
  chunk_output_type: console
nocite: "@*"
---

```{r}
#| include: false

library(data.table)
library(ggplot2)
library(stringr)
library(purrr)
library(ggh4x)
library(gt)

ggplot2::theme_set(ggthemes::theme_few())
theme_update(panel.grid = element_line(color = "#f0f0f0"))

# Color schemes (uchicago):
#   Default: default_uchicago:
#     #800000 #767676 #FFA319 #8A9045 #155F83 
#     #C16622 #8F3931 #58593F #350E20
#   Dark: dark_uchicago:
#     #800000 #767676 #CC8214 #616530 #0F425C 
#     #9A5324 #642822 #3E3E23 #350E20 
#   Light: light_uchicago:
#     #800000 #D6D6CE #FFB547 #ADB17D #5B8FA8 
#     #D49464 #B1746F #8A8B79 #725663
#   White:
#     #FFFAFA #FCFCFC #FFFDFD #FCFFE0 #F9FCFF 
#     #FFFCFB #FFFAFA #FCFDE5 #FFF8FA
```

## Outline {.ai .dark .columns background-image="Images/AI/Steps-Spiral.jpg" background-position="right" background-size="auto 100%"}

::: {.column width="50%"}
-   [Background](#background)

-   [Case series](#case-series)

-   [Methods and Results](#method-and-results)

-   [Summary](#summary)
:::

::: {.column width="50%"}
:::

# Research Objective  {.center .middle #aim}

To examine ***melanoma survival*** and ***trend*** by tumour thickness in overall and in important subgroups such as *sex* and *age* in a unique nationwide case series over a 35-year time period.

# Background {.center .middle .huge background-color="#767676FF"}

## Data from Cancer Registry of Norway (CRN) {.middle}

::: {.columns .grid}
::: {.column style="font-size: 120%;"}
::: {.callout-note icon="false" appearance="minimal"}
*Histologically verified* data
:::
::: {.callout-note icon="false" appearance="minimal"}
*Tumour thickness* recorded since 1980 are *now digitized*
:::
::: {.callout-note icon="false" appearance="minimal"}
*Melanoma registry* established in 2008 under CRN provides the data
:::
::: {.callout-tip icon="false" appearance="minimal"}
Here we will use data from *1983 to 2019*
:::
:::

::: {.column}
![](Images/Logos/CRN-Logo-NoText.svg){fig-align="right"}
:::
:::

## Melanoma and tumour thickness 

### T-categories

![Source: [`https://www.cancerresearchuk.org/about-cancer/melanoma/stages-types/tnm-staging`](https://www.cancerresearchuk.org/about-cancer/melanoma/stages-types/tnm-staging)](Images/T-Stages.svg){width="100%" fig-align="center"}

<!--
::: {.absolute .fragment .fade-in-then-out .fade-out data-id="box1" style="border: 2px solid #800000; width: 130px; height: 90px; margin: 10px; background: #80000011; border-radius: 10%;" top="18%" left="30%"}
:::

::: {.absolute .fragment .fade-right .fade-in-then-out data-id="box1" style="border: 2px solid #800000; width: 130px; height: 90px; margin: 10px; background: #80000022; border-radius: 10%;" top="18%" left="42%"}
:::

::: {.absolute .fragment .fade-right .fade-in-then-out data-id="box1" style="border: 2px solid #800000; width: 130px; height: 90px; margin: 10px; background: #80000033; border-radius: 10%;" top="18%" left="57%"}
:::

::: {.absolute .fragment .fade-right .fade-in-then-out data-id="box1" style="border: 2px solid #800000; width: 130px; height: 90px; margin: 10px; background: #80000044; border-radius: 10%;" top="18%" left="70%"}
:::
-->

# Case series {.center .middle .huge background-color="#155F83FF"}

## Basic characteristics of data {background-transition="none" transition="none" background-image="Images/Characteristics-Age.PNG" background-size="90% auto" background-position="center 80%"}

::: {.callout-note icon="false"}
### Age at diagnosis

Age at diagnosis has increased in the recent period (2008--2019).
:::

## Basic characteristics of data {background-transition="none" transition="none" background-image="Images/Characteristics-Thickness.PNG" background-size="90% auto" background-position="center 80%"}

::: {.callout-note icon="false"}
### Tumour thickness

The thickness of tumour at diagnosis has decreased in the recent period (2008--2019).
:::

# Methods and Results  {.center .middle .huge background-color="#3E3E23"}

# Relative Survival {.center .middle background-color="#FCFDE5"}

_Relative survival_[^1] **compares the survival of people with melanoma with those who don't** over a certain period of time.

[^1]: Relative survival is the _ratio of "proportion of observed survival" to the "proportion of expected survival"_ in a cohort of cancer patients.

## Relative survival {.smaller .middle}

::: {.columns .grid style="grid-template-columns: 1fr 2fr; align-items: end;"}
::: column

**By sex and T category**

::: {.callout-note appearance="simple" icon="false"}
Patients with thinner melanoma (T1) have similar survival as general population.
:::

::: {.callout-note appearance="simple" icon="false"}
The 5-year survival for patients with T4 melanoma is less than 60%
compared to general population.
:::

::: {.callout-note appearance="simple" icon="false"}
Men have lower survival compared to women in all T-categories.
:::

::: {.callout-note appearance="simple" icon="false"}
Clear difference in survival by T-categories reflects the importants
of tumour thickness in prognosis.
:::

:::
::: column
![](plots/surv-by-sex-tstage-ci.svg){width="100%"}
:::
:::

## Relative survival {.smaller .middle}

::: {.columns .grid style="grid-template-columns: 1fr 2fr; align-items: end;"}
::: column

**By sex and T category**
**Before and After 2000**

::: {.callout-note appearance="simple" icon="false"}
Changes in long-term survival of T1 and T3 melanoma diagnosed from 2000 is larger in men than in women compared to those diagnosed before 2000.
:::

::: {.callout-note appearance="simple" icon="false"}
In T4 melanoma, only small change is observed in men.
:::

:::
::: column
![](plots/surv-by-sex-tstage.svg){width="100%"}
:::
:::

# Cumulative mortality {.center .middle background-color="#FCFDE5"}

The cumulative mortality [^1] up to a given time is the probability of an individual dying by that time[^2].

[^1]: Cumulative mortality (cumulative incidence of death) refers to the event of death due to melanoma.
[^2]: Total cases can be divided into proportion of alive, death due to other causes and death due to melanoma.

## Cumulative Mortality {.smaller .middle}

::: {.columns .grid style="grid-template-columns: 1fr 2fr; align-items: end;"}
::: column

**By sex and T category**

::: {.callout-note appearance="simple" icon="false"}
The probability of other cause of death does not change drastically as the probability of melanoma death between T categories.
:::

::: {.callout-note appearance="simple" icon="false"}
The proportion of melanoma deaths grows as tumour thickness increases.
:::

::: {.callout-note appearance="simple" icon="false"}
Men have poor prognosis compared to women (high cumulative incidence).
:::

::: {.callout-tip appearance="minimal" icon="false"}
Younger population has more thinner and older has more thicker cases. In longer follow-up, we see an increasing probability in both melanoma an other cause of death.
:::
:::
::: column
![](plots/cuminc-by-sex-tstage.svg){width="100%"}
:::
:::

## Is this the effect of treatment? {.smaller .middle}

::: {.columns .grid style="grid-template-columns: 1fr 2fr; align-items: end;"}

::: column 

**Melanoma with distant metastasis**

::: {.callout-tip appearance="simple" icon="false"}
Comparing cumulative incidence within distant metastasis cases diagnosed between 2008--2013 and 2014--2019, we observed a drop in melanoma specific deaths in the later period.
:::

::: {.callout-note appearance="simple" icon="false"}
Around year 2014, new treatment immunotherapy was introduced in stage IV melanoma.
:::

:::
::: column
![](plots/cuminc-treatment-effect.svg){width="100%"}
:::
:::

## Is this the effect of treatment? {.smaller .middle}

::: {.columns .grid style="grid-template-columns: 1fr 2fr; align-items: end;"}

::: column 

**Melanoma with distant metastasis**

::: {.callout-tip appearance="simple" icon="false"}
No interaction between sex and period of diagnosis
:::

::: {.callout-note appearance="simple" icon="false"}
Based on model without interaction:

  - Male have higher mortality than female
  - Period 2014-2016 has lower mortality than the period 2011-2013
:::


::: {.callout-note appearance="simple" icon="false"}
Around year 2014, new treatment immunotherapy was introduced in stage IV melanoma.
:::

:::
::: column
![](plots/cox-model-treatment.svg){width="100%"}
:::
:::


# Conditional Relative Survival {.center .middle background-color="#FCFDE5"}

Relative survival of a melanoma patients surviving a certain number of year (y) _given that the patients has already survived_ a fixed number of years (x) since diagnosis.

## {.smaller .middle}

::: {.columns .grid style="grid-template-columns: 1fr 2fr; align-items: end;"}
::: column
### Conditional 5-year Relative Survival

::: {.callout-info appearance="simple" icon="false"}
The dashed line represents the 5 and 10-year relative survival after the patients survived for 0, 1, 2, 3, ... years (scale in grey color). 
:::

::: {.callout-note appearance="simple" icon="false"}
We see that in all T-categories, both 5-year and 10-year relative survival condition on surviving certain number of years starts to becomes similar when the conditional year increases.
:::

::: {.callout-note appearance="simple" icon="false"}
For example, two patients diagnosed with T1 and T3 melanoma respectively have similar 5-year relative survival after surviving from 15 years.
:::

:::
::: column
![](plots/cond-surv-by-sex-tstage-crn.svg){width="100%"}
:::
:::

# Trend in relative survival {.center .middle background-color="#FCFDE5"}

Changes in relative survial over time.

## Relative turvival Trend {.smaller .middle}

::: {.columns .grid style="grid-template-columns: 1fr 2fr; align-items: end;"}
::: column

**Relative survival**

**10-years follow-up**

::: {.callout-note appearance="simple" icon="false"}
The 10-year relative survival in all T-categories has stable or slight increasing trend. 
:::

::: {.callout-note appearance="simple" icon="false"}
In the case of thicker melanoma, women have higher increasing trend in T4 melanoma and men have in T3.
:::
:::

::: column
![](plots/trend-by-sex-tstage-llm.svg){width="100%"}
:::
:::

# Summary {.center .middle .huge background-color="#642822"}

## Summary {.ai .dark background-image="Images/AI/Overview-Lake-Boat.jpg" background-position="right" background-size="auto 100%"}

::: {.columns .grid style="grid-template-columns: 1fr 1fr; align-items: end;"}
::: column
::: {.callout-note appearance="simple" icon="false"}
-   Despite _stable melanoma mortality_ was seen in cancer reports in Norway for last few years, Norway _ranks second in mortality_ worldwide.
:::
::: {.callout-important appearance="simple" icon="false"}
-   Older men diagnosed more with _thicker melanoma_ and has _higher mortality_
:::

::: {.callout-tip appearance="simple" icon="false"}
-   Awareness focused on *elderly males* may be effective for *early detection*.
-   _Risk stratification_ and _targeted_ screening
:::
:::

::: column
:::
:::

# {visibility="hidden"}

##  {#logo-profile .center .smaller}

::: columns
::: {.column width="30%"}
### Collaborators

::: collab-logo
![](Images/Logos/UiO-Logo.png){#uio width="100%"} ![](Images/Logos/CRN-Logo.svg){#crn width="100%"} ![](Images/Logos/QIMR-Logo.png){#qimr width="100%"} ![](Images/Logos/IARC-Logo.png){#iarc width="100%"} ![](Images/Logos/OCBE-Logo.png){#ocbe width="100%"} ![](Images/Logos/OUS-Logo.png){#ous width="100%"} ![](Images/Logos/RNF-Logo.svg){#rnf width="100%"}
:::
:::

::: {.column width="70%"}
### Coauthors

::: profile-container
```{r}
#| results: asis
imgs <- dir("Images/Profile", pattern = "^\\d.*profile.*\\.png", full.names = TRUE)
names(imgs) <- gsub(".*\\/\\d{2}-profile-(.*)\\.png", "\\1", imgs) %>% 
    stringr::str_replace_all("-", " ") %>% 
    stringr::str_to_title()
iwalk(imgs, function(img, name) {
  glue::glue(
    '::: {{.profile-card}}',
    '![]({img}){{width="100%"}}',
    '<p>{name}</p>',
    ':::',
    .sep = "\n"
  ) %>% print()
})
```
:::

::: {#funding}
**Funded by:** The Research Council of Norway.
:::
:::
:::

##  {background-image="Images/Thank-You.png" background-size="auto 90%"}

## References {.smaller}

::: {#refs}
:::
